Dr. Abdullah Mubarak, MD
Hepatology (Transplant Hepatology Physician)
- Medicare participating
At a glance
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 304
Licensed in Texas since 2006, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Transplant Hepatology Physician primary
TX license M5390 (first issued 2006; active) -
Hepatology Physician
TX license M5390 (first issued 2006; active) -
Internal Medicine Physician
TX license M5390 (first issued 2006; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ut of Texas Southwestern University Hospital - William P. Clements Jr. Dallas, TX
- Christus Mother Frances Hospital Tyler, TX
- Christus Mother Frances Hospital Sulphur Springs Sulphur Springs, TX
- Christus Mother Frances Hospital- Jacksonville Jacksonville, TX
Medical groups
- Christus Trinity Clinic Texas (1,540 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 304
- Services billed
- 683
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 249 | 120 |
| Established patient office or other outpatient visit, 30-39 minutes | 92 | 75 |
| Ultrasound scan of organ tissue for measuring elasticity | 82 | 77 |
| New patient office or other outpatient visit, 60-74 minutes | 51 | 51 |
| New patient office or other outpatient visit, 45-59 minutes | 29 | 29 |
| Measurement of liver stiffness | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ursodiol Other prescribers in Tyler, TX | 280 |
| Furosemide Other prescribers in Tyler, TX | 190 |
| Xifaxan (rifaximin) Other prescribers in Tyler, TX | 184 |
| Carvedilol Other prescribers in Tyler, TX | 162 |
| Spironolactone Other prescribers in Tyler, TX | 112 |
| Mycophenolate Mofetil Other prescribers in Tyler, TX | 111 |
| Vemlidy (tenofovir alafenamide) | 83 |
| Lactulose Other prescribers in Tyler, TX | 64 |
| Amiloride Hcl | 45 |
| Prednisone Other prescribers in Tyler, TX | 40 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 173 payments worth $110,464 in total to this clinician.
| Madrigal Pharmaceuticals | $30,462 |
|---|---|
| Ipsen Biopharmaceuticals, Inc | $30,415 |
| Gilead Sciences, Inc. | $25,690 |
| AbbVie Inc. | $23,291 |
| Intercept Pharmaceuticals, Inc. | $253 |
| Kerecis Limited | $187 |
| Intra-sana Laboratories | $60.35 |
| Novo Nordisk Inc | $36.82 |
| Compensation for services other than consulting (speaking, faculty) | $94,012 |
|---|---|
| Travel and Lodging | $6,445 |
| Consulting Fee | $5,470 |
| Food and Beverage | $4,537 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Jul 30, 2025 | Compensation for services other than consulting (speaking, faculty) MAVYRET · VIROLOGY | $6,400 |
| Ipsen Biopharmaceuticals, Inc Oct 18, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,967 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,738 |
| AbbVie Inc. Jun 25, 2025 | Compensation for services other than consulting (speaking, faculty) MAVYRET · VIROLOGY | $5,600 |
| AbbVie Inc. Aug 8, 2025 | Compensation for services other than consulting (speaking, faculty) MAVYRET · VIROLOGY | $5,600 |
| Gilead Sciences, Inc. Jun 27, 2025 | Consulting Fee Livdelzi · INFLAM Company’s description;4146683;VEM US;10049209 | $5,470 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $5,288 |
| Ipsen Biopharmaceuticals, Inc Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,049 |
| Ipsen Biopharmaceuticals, Inc Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,049 |
| Ipsen Biopharmaceuticals, Inc Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,049 |
All 42 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Madrigal Pharmaceuticals Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $1,763 |
| Ipsen Biopharmaceuticals, Inc Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,049 |
| Ipsen Biopharmaceuticals, Inc Nov 6, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Washington, DC · in-kind | $911 |
| Ipsen Biopharmaceuticals, Inc Nov 6, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Washington, DC · in-kind | $453 |
| Gilead Sciences, Inc. Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4257481;AHM;10049209 | $3,790 |
| Ipsen Biopharmaceuticals, Inc Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,049 |
| Ipsen Biopharmaceuticals, Inc Oct 29, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Arlington, TX · in-kind | $36.40 |
| Ipsen Biopharmaceuticals, Inc Oct 18, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,967 |
| Ipsen Biopharmaceuticals, Inc Oct 18, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Denver, CO · in-kind | $1,036 |
| Madrigal Pharmaceuticals Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Madrigal Pharmaceuticals Aug 14, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| AbbVie Inc. Aug 8, 2025 | Compensation for services other than consulting (speaking, faculty) MAVYRET · VIROLOGY | $5,600 |
| Madrigal Pharmaceuticals Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| AbbVie Inc. Jul 31, 2025 | Travel and Lodging MAVYRET · VIROLOGY · travel to DENVER, CO · in-kind | $64.00 |
| AbbVie Inc. Jul 31, 2025 | Travel and Lodging MAVYRET · VIROLOGY · travel to DENVER, CO · in-kind | $33.32 |
| AbbVie Inc. Jul 30, 2025 | Compensation for services other than consulting (speaking, faculty) MAVYRET · VIROLOGY | $6,400 |
| AbbVie Inc. Jul 24, 2025 | Travel and Lodging MAVYRET · VIROLOGY · travel to CINCINNATI, OH · in-kind | $107 |
| AbbVie Inc. Jul 21, 2025 | Compensation for services other than consulting (speaking, faculty) MAVYRET · VIROLOGY | $4,000 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $5,288 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX | $30.52 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX | $25.98 |
| Gilead Sciences, Inc. Jul 17, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to South San Francisco, CA Company’s description;4147261;VEM US;10049209 | $64.00 |
| Gilead Sciences, Inc. Jul 17, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to South San Francisco, CA Company’s description;4147248;VEM US;10049209 | $29.40 |
| AbbVie Inc. Jul 11, 2025 | Travel and Lodging MAVYRET · VIROLOGY · travel to DENVER, CO · in-kind | $346 |
| AbbVie Inc. Jul 11, 2025 | Travel and Lodging MAVYRET · VIROLOGY · travel to DENVER, CO · in-kind | $310 |
| AbbVie Inc. Jul 11, 2025 | Travel and Lodging MAVYRET · VIROLOGY · travel to DENVER, CO · in-kind | $40.00 |
| Gilead Sciences, Inc. Jun 27, 2025 | Consulting Fee Livdelzi · INFLAM Company’s description;4146683;VEM US;10049209 | $5,470 |
| AbbVie Inc. Jun 25, 2025 | Compensation for services other than consulting (speaking, faculty) MAVYRET · VIROLOGY | $5,600 |
| Gilead Sciences, Inc. Jun 12, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to South San Francisco, CA · in-kind Company’s description;4147097;VEM US;10049209 | $584 |
| Gilead Sciences, Inc. Jun 12, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to South San Francisco, CA · in-kind Company’s description;4147089;VEM US;10049209 | $367 |
| AbbVie Inc. Jun 5, 2025 | Travel and Lodging MAVYRET · VIROLOGY · travel to CINCINNATI, OH · in-kind | $136 |
| Madrigal Pharmaceuticals May 8, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Gilead Sciences, Inc. Apr 22, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;4114324;AHM;10049209 | $4,930 |
| Madrigal Pharmaceuticals Apr 15, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Gilead Sciences, Inc. Apr 8, 2025 | Travel and Lodging Epclusa · HCV · travel to Longview, TX · in-kind Company’s description;4098549;AHM;10049209 | $1,002 |
| Ipsen Biopharmaceuticals, Inc Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,049 |
| Gilead Sciences, Inc. Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;4111800;AHM;10049209 | $3,790 |
| Madrigal Pharmaceuticals Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $2,820 |
| Gilead Sciences, Inc. Mar 1, 2025 | Travel and Lodging Epclusa · HCV · travel to Atlanta, GA · in-kind Company’s description;4026741;GTF;10049209 | $569 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,738 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Dallas, TX · in-kind | $299 |
| Gilead Sciences, Inc. Feb 3, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;4128484;AHM;10049209 | $3,790 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $499,675 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals · Active, not recruiting · NCT04951219 - A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
Bausch Health US, LLC - A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)…
Gilead Sciences, Inc. - Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
Ipsen Bioscience Inc. · Active, not recruiting · NCT04526665 - A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
Ipsen Pharma Sas · Active, not recruiting · NCT06447168
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.